Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis

Nathan, Steven D, Albera, Carlo, Bradford, Williamson Z, Costabel, Ulrich, Glaspole, Ian, Glassberg, Marilyn K, Kardatzke, David R, Daigl, Monica +7 more·2017·The Lancet Respiratory Medicine

DOI 10.1016/s2213-2600(16)30326-5

Cited by (337)

Items 101–200 of 337

Human placental mesenchymal stem cells of fetal origins-alleviated inflammation and fibrosis by attenuating MyD88 signaling in bleomycin-induced pulmonary fibrosis mice
Feng Li, Fei Han, Hui Li, Jia Zhang, Xia Qiao, Juan Shi, Yang Li, Jianda Dong, Meihui Luo, Jun Wei et al. · 2017 · Molecular Immunology
Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis
Satoshi Ikeda, Akimasa Sekine, Tomohisa Baba, Takuma Katano, Erina Tabata, Ryota Shintani, Shinko Sadoyama, Hideaki Yamakawa, T. Oda, Ryo Okuda et al. · 2019 · BMC Pulmonary Medicine
Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis
Carlo Vancheri, Alfredo Sebastiani, Sara Tomassetti, Alberto Pesci, Paola Rogliani, Laura Maria Tavanti, Fabrizio Luppi, Sergio Alfonso Harari, Paola Rottoli, Alessandra Ghirardini et al. · 2019 · Respiratory Medicine
The association between white blood cell count and outcomes in patients with idiopathic pulmonary fibrosis
Steven D. Nathan, Anne Whitney Brown, Nesrin Moğulkoç, Flavia de Souza Nunes Soares, Ashley Collins, Joyce M. Cheng, J. Peterson, Brenna Cannon, Christopher S. King, Scott Douglas Barnett · 2020 · Respiratory Medicine
Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis
Xiang-Lin Zhou, Dan-Hui Yang, Xiang-long Kong, Chen Wei, S. Lvqiu, Lin Wang, Yon-Rong Lin, Zhilan Yin, Zhi-Guo Zhou, Hong Luo · 2022 · Frontiers in Medicine
Idiopathic pulmonary fibrosis: a holistic approach to disease management in the antifibrotic age
Jonathon Shaw, Tracey Marshall, Helen G. Morris, Conal Hayton, Nazia Chaudhuri · 2017 · Journal of Thoracic Disease
Lung transplantation for idiopathic pulmonary fibrosis
Jérôme Le Pavec, Gaëlle Dauriat, Pierre Gazengel, Samuel Dolidon, Amir Hanna, Severine Feuillet, Pauline Pradère, Adrian Crutu, Valentina Florea, David Boulate et al. · 2020 · La Presse Médicale
In-hospital mortality trends among patients with idiopathic pulmonary fibrosis in the United States between 2013-2017: a comparison of academic and non-academic programs
Shehabaldin Alqalyoobi, Evans R. Fernández Pérez, Justin M. Oldham · 2020 · BMC Pulmonary Medicine
Endobronchial autologous bone marrow–mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial
Arantza Campo, José María González‐Ruiz, Enrique José Andreu, Ana B. Alcaide, María del Mar Ocón, Juan Pablo de-Torres, Jesús C. Pueyo, Rosa Cordovilla, Eva M. Villarón, Fermin M. Sanchez-Guijo et al. · 2021 · ERJ Open Research
Pirfenidone ameliorates early pulmonary fibrosis in LPS-induced acute respiratory distress syndrome by inhibiting endothelial-to-mesenchymal transition via the Hedgehog signaling pathway
Renzi Zhang, Yiwen Tan, Chaoying Yong, Yang Jiao, Xumao Tang, Daoxin Wang · 2022 · International Immunopharmacology
Enriched collagen solution as a pulp dressing in pulpotomized teeth in monkeys.
Anna B. Fuks, Yael Michaeli, B Sofer-Saks, S. Shoshan · 1984 · PubMed
The self-fulfilling prophecy of pulmonary fibrosis: a selective inspection of pathological signalling loops
Ashley R. Rackow, David J. Nagel, Claire McCarthy, Jennifer Judge, Shannon H. Lacy, M.A.T. Freeberg, Thomas H. Thatcher, Robert Matthew Kottmann, Patricia J. Sime · 2020 · European Respiratory Journal
Evolution and treatment of idiopathic pulmonary fibrosis
Sebastiano Emanuele Torrisi, Nicolas Carlos Kahn, Carlo Vancheri, Michael Kreuter · 2020 · La Presse Médicale
Central Role of CT in Management of Pulmonary Fibrosis
Kum Ju Chae, Hye Jeon Hwang, Rosane Duarte Achcar, Joseph C. Cooley, Stephen M. Humphries, Seth J. Kligerman, David A. Lynch · 2024 · Radiographics
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis
Shambhu Aryal, Steven D. Nathan · 2018 · Expert Opinion on Emerging Drugs
Effect of Antifibrotic Therapy on Survival in Patients With Idiopathic Pulmonary Fibrosis
João A. de Andrade, Megan Lee Neely, Anne S. Hellkamp, Daniel A. Culver, Hyun J. Kim, Timothy N. Liesching, Leonard Jason Lobo, Murali Ramaswamy, Zeenat Safdar, Shaun D. Bender et al. · 2022 · Clinical Therapeutics
Effects of Exercise Training on Cardiopulmonary Function and Quality of Life in Elderly Patients with Pulmonary Fibrosis: A Meta-Analysis
Xiaohan Li, Rongfang Yu, Ping Wang, Aiwen Wang, Huiming Huang · 2021 · International Journal of Environmental Research and Public Health
Fatty acid nitroalkene reversal of established lung fibrosis
Adolf Koudelka, Veronika Cechova, Mauricio M. Rojas, Nilay Mitash, Anna Bondonese, Claudette M. St. Croix, Mark A. Ross, Bruce Α. Freeman · 2021 · Redox Biology
Acute exacerbation of chronic fibrosing interstitial pneumonia in patients receiving antifibrotic agents: incidence and risk factors from real-world experience
Kodai Kawamura, Kazuya Ichikado, Hidenori Ichiyasu, Keisuke Anan, Yuko Unnai Yasuda, Moritaka Suga, Takuro Sakagami · 2019 · BMC Pulmonary Medicine
Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options
Athina Trachalaki, Mujammil Irfan, Athol Umfrey Wells · 2020 · Expert Opinion on Pharmacotherapy
Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension
Oksana A. Shlobin, Eric Shen, Stephen John Wort, Lucilla Piccari, John Scandurra, Paul M. Hassoun, Sylvia M. Nikkho, Steven D. Nathan · 2024 · Pulmonary Circulation
Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias
Michael Kreuter, Julia Wälscher, Jürgen Behr · 2017 · Current Opinion in Pulmonary Medicine
New trajectories in the treatment of interstitial lung disease
Julie Morisset, Joyce Sujin Lee · 2019 · Current Opinion in Pulmonary Medicine
Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy – the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial
For the CleanUP-IPF Study Team, Kevin Joseph Anstrom, Imre Noth, Kevin R. Flaherty, Rex Edwards, Joan Albright, Amanda Baucom, Maria M. Brooks, Allan Clark, Emily Siu Clausen et al. · 2020 · Respiratory Research
Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients
Haoshen Feng, Yabin Zhao, Zhenhua Li, Jian Kang · 2020 · Therapeutic Advances in Respiratory Disease
Insights from Transcriptomics: CD163+ Profibrotic Lung Macrophages in COVID-19
Mallar Bhattacharya · 2022 · American Journal of Respiratory Cell and Molecular Biology
Co‐morbidity and mortality among patients with interstitial lung diseases: A population‐based study
Ole Hilberg, Elisabeth M. Bendstrup, Anders Løkke, Rikke Ibsen, Andreas Fløe, Charlotte Hyldgaard · 2017 · Respirology
Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction
Astrid Weiß, Mario Boehm, Bakytbek Egemnazarov, Friedrich Grimminger, Soni Savai Pullamsetti, Grażyna Kwapiszewska, RALPH THEO SCHERMULY · 2019 · British Journal of Pharmacology
Prognosis of pulmonary fibrosis presenting with a usual interstitial pneumonia pattern on computed tomography in patients with myeloperoxidase anti-neutrophil cytoplasmic antibody-related nephritis: a retrospective single-center study
Toshikazu Watanabe, Tomoyuki Minezawa, Midori Hasegawa, Yasuhiro Gotô, Takuya Okamura, Yosuke Sakakibara, Yoshikazu Niwa, Atsushi Kato, Masamichi Hayashi, Sumito Isogai et al. · 2019 · BMC Pulmonary Medicine
The novel role of ER protein TXNDC5 in the pathogenesis of organ fibrosis: mechanistic insights and therapeutic implications
Chen‐Ting Hung, Yi-Wei Tsai, Yu‐Shuo Wu, Chih‐Fan Yeh, Kai‐Chien Yang · 2022 · Journal of Biomedical Science
Idiopathic pulmonary fibrosis: Diagnosis, biomarkers and newer treatment protocols
Harshank Patel, Jui Rakesh Shah, Divya Patel, Chaithanya Avanthika, Sharan Jhaveri, Kunj Gor · 2022 · Disease-a-Month
Pharmakotherapie der idiopathischen Lungenfibrose (ein Update) und anderer progredienter pulmonaler Fibrosen
Jürgen Behr, Francesco Bonella, Björn C. Frye, Andreas Günther, Lars Hagmeyer, Jörg C. Henes, Philipp Klemm, Dirk Koschel, Michael Kreuter, Gabriela Leuschner et al. · 2023 · Pneumologie
Deep learning diagnostic and severity-stratification for interstitial lung diseases and chronic obstructive pulmonary disease in digital lung auscultations and ultrasonography: clinical protocol for an observational case–control study
Johan Nicolas Siebert, Mary‐Anne Hartley, Delphine Sophie Courvoisier, Marlène Salamin, Laura Robotham, Jonathan Doenz, Constance Barazzone‐Argiroffo, Alain Gervaix, Pierre‐Olivier Bridevaux · 2023 · BMC Pulmonary Medicine
Targeting Progression in Pulmonary Fibrosis: An Overview of Underlying Mechanisms, Molecular Biomarkers, and Therapeutic Intervention
Vito D’Agnano, Domenica Francesca Mariniello, Michela Ruotolo, Gianluca Quarcio, Alessandro Moriello, Stefano Conte, Antonio Sorrentino, Stefano Sanduzzi Zamparelli, Andrea Bianco, Fabio Perrotta · 2024 · Life
A Phase 1b Study of Vismodegib with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Antje Prasse, Murali Ramaswamy, Shaun Mohan, Lin Pan, Andrew Kenwright, Margaret Neighbors, Paula Belloni, Peter P. LaCamera · 2019 · Pulmonary Therapy
Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg)
Ekaterina Krauss, Silke Tello, Jochen Wilhelm, Johanna Schmidt, Mark Stoehr, Werner Seeger, Ruth Charlotte Dartsch, Bruno Crestani, Andreas Günther · 2020 · Journal of Clinical Medicine
Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis
Yuzo Suzuki, Kazutaka Mori, Yuya Aono, Masato Kono, Hirotsugu Hasegawa, Koshi Yokomura, Hyogo Naoi, Hironao Hozumi, Masato Karayama, Kazuki Furuhashi et al. · 2021 · Scientific Reports
BAL Transcriptomes Characterize Idiopathic Pulmonary Fibrosis Endotypes With Prognostic Impact
Laurens De Sadeleer, Stijn E. Verleden, Jonas C. Schupp, John E. McDonough, Tinne Goos, Jonas Yserbyt, Elena Bargagli, Paola Rottoli, Naftali Kaminski, Antje Prasse et al. · 2022 · CHEST Journal
Evaluation of Proteasome Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis
I‐Chen Chen, Yi‐Ching Liu, Yen-Hsien Wu, Shih‐Hsing Lo, Zen‐Kong Dai, Jong‐Hau Hsu, Yu‐Hsin Tseng · 2022 · Cells
COVID-19 and interstitial lung diseases: A multifaceted look at the relationship between the two diseases
Jun Fukihara, Yasuhiro Kondoh · 2023 · Respiratory Investigation
A 2-Year Observational Study in Patients Suffering from Idiopathic Pulmonary Fibrosis and Treated with Pirfenidone: A French Ancillary Study of PASSPORT
S. Jouneau, Anne Sophie Gamez, Julie Traclet, Hilario Nunès, Sylvain Marchand-Adam, Romain Kessler, Dominique Israël‐Biet, Raphaël Borie, Indiana Strombom, Astrid Scalori et al. · 2019 · Respiration
Obstacles to early treatment of idiopathic pulmonary fibrosis: current perspectives
Teng Moua, Jay Hoon Ryu · 2019 · Therapeutics and Clinical Risk Management
Cell Therapy for Idiopathic Pulmonary Fibrosis: Rationale and Progress to Date
Paschalis Ntolios, Paschalis Steiropoulos, Georgia Karpathiou, Stavros Anevlavis, Τheodoros Karampitsakos, Evangelos Bouros, Μarios E. Froudarakis, Demosthenes E. Bouros, Argyrios Tzouvelekis · 2020 · BioDrugs
Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience
Stefano Levra, Giuseppe Guida, Andrea Elio Sprio, Flavio Crosa, Paolo Carlo Ghio, Francesca Bertolini, Vitina Maria Anna Carriero, Carlo Albera, Fabio Luigi Massimo Ricciardolo · 2022 · Biomedicines
New treatment directions for IPF: current status of ongoing and upcoming clinical trials
Francesco Macagno, Francesco Varone, Paolo Maria Leone, Pier‐Valerio Mari, Loredana Panico, Ludovica Berardini, Luca Richeldi · 2017 · Expert Review of Respiratory Medicine
Mortality and Respiratory-Related Hospitalizations in Idiopathic Pulmonary Fibrosis Not Treated With Antifibrotics
Vincent Cottin, Paolo Spagnolo, Philippe Bonniaud, Maëva Nolin, Faustine Dalon, Klaus-Uwe Kirchgässler, Tripthi V Kamath, Eric H. Van Ganse, Manon Belhassen · 2021 · Frontiers in Medicine
Bexotegrast Shows Dose-Dependent Integrin αvβ6 Receptor Occupancy in Lungs of Participants with Idiopathic Pulmonary Fibrosis: A Phase 2, Open-Label Clinical Trial
Joshua J. Mooney, Susan S. Jacobs, Eric A Lefebvre, Gregory P. Cosgrove, Annie Clark, Scott Turner, Martin L. Decaris, Chris N. Barnes, Marzena Jurek, Brittney Williams et al. · 2024 · Annals of the American Thoracic Society
Epidemiology of Pulmonary Fibrosis: A Cohort Study Using Healthcare Data in Sweden
Giovanni Ferrara, Lisen Arnheim‐Dahlström, Karen Bartley, Christer Janson, Klaus-Uwe Kirchgässler, AARON M. LEVINE, Carl Magnus Sköld · 2019 · Pulmonary Therapy
Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review
Saskia Bos, Laurens De Sadeleer, Arno Vanstapel, Hanne Beeckmans, Annelore Sacreas, Jonas Yserbyt, Wim A Wuyts, Robin Vos · 2021 · European Respiratory Review
An update on current and emerging drug treatments for idiopathic pulmonary fibrosis
Athina Trachalaki, Nasrin Sultana, Athol Umfrey Wells · 2023 · Expert Opinion on Pharmacotherapy
JTE-013 Alleviates Pulmonary Fibrosis by Affecting the RhoA/YAP Pathway and Mitochondrial Fusion/Fission
J. Zhou, Yilan Song, Xingmei Wang, Xinrui Li, Chang Liu, Chenchen Tian, Chongyang Wang, Liangchang Li, Guanghai Yan, Hong Cui · 2023 · Pharmaceuticals
Pulmonary fibrosis, part II: state-of-the-art patient management
Keith C. Meyer · 2017 · Expert Review of Respiratory Medicine
Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel <scp>prolyl‐tRNA</scp> synthetase inhibitor, in healthy subjects
Park, Min Young, Bae, Sungyeun, Heo, Jung A, Park, Mihee, Kim, YuKyung, Han, Jumi, Jang, In‐Jin, Yu, Kyung‐Sang, Oh, Jaeseong · 2023 · Clinical and Translational Science
Idiopathic pulmonary fibrosis: current diagnosis and treatment
Alexandre Franco Amaral, Philippe de Figueiredo Braga Colares, Ronaldo Adib Kairalla · 2023 · Jornal Brasileiro de Pneumologia
Evidence from recent clinical trials in fibrotic interstitial lung diseases
Vincent Cottin, Claudia Valenzuela · 2024 · Current Opinion in Pulmonary Medicine
Human respiratory airway progenitors derived from pluripotent cells generate alveolar epithelial cells and model pulmonary fibrosis
Mikael G. Pezet, Juan A. Torres, Tania Ahalya Thimraj, Ivana Matković, Nadine Schrode, John W. Murray, Anjali Saqi, Kristin G. Beaumont, Hans‐Willem Snoeck · 2025 · Nature Biotechnology
Novel management strategies for idiopathic pulmonary fibrosis
Kareem Ahmad, Steven D. Nathan · 2018 · Expert Review of Respiratory Medicine
Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodology
José Antônio Baddini Martínez, Juliana Carvalho Ferreira, Suzana Érico Tanni, Luis Renato Alves, Benedito Francisco Cabral, Carlos Roberto Ribeiro de Carvalho, Talita Jacon Cezare, Cláudia Henrique da Costa, Marcelo Basso Gazzana, Sérgio Fernandes de Oliveira Jezler et al. · 2020 · Jornal Brasileiro de Pneumologia
Recent advances in managing idiopathic pulmonary fibrosis
Chiara Scelfo, Antonella Caminati, Sergio Alfonso Harari · 2017 · F1000Research
A comprehensive and practical approach to the management of idiopathic pulmonary fibrosis
Onofre Moran‐Mendoza, Rebecca Colman, Meena Kalluri, Czerysh Cabalteja, Ingrid A. Harle · 2019 · Expert Review of Respiratory Medicine
Natural products for anti-fibrotic therapy in idiopathic pulmonary fibrosis: marine and terrestrial insights
Meili Ma, Zhengqi Chu, Hongyu Quan, Hua Li, Yuran Zhou, Yanhong Han, Kefeng Li, Wenjun Pan, Deyun Wang, Yan Yan et al. · 2025 · Frontiers in Pharmacology
Multidisciplinary Approach to the Diagnosis of Idiopathic Interstitial Pneumonias: Focus on the Pathologist’s Key Role
Stefano Lucà, Francesca Pagliuca, Fabio Perrotta, Andrea Ronchi, Domenica Francesca Mariniello, Giovanni Natale, Andrea Bianco, Alfonso Fiorelli, Marina Accardo, Renato Franco · 2024 · International Journal of Molecular Sciences
Revolutionizing the Treatment of Idiopathic Pulmonary Fibrosis: From Conventional Therapies to Advanced Drug Delivery Systems
Sanskriti Singh, Sarika Wairkar · 2024 · AAPS PharmSciTech
Existing and emerging treatments for idiopathic pulmonary fibrosis
Lykourgos Kolilekas, Spyridon A. Papiris, Demosthenes E. Bouros · 2019 · Expert Review of Respiratory Medicine
Drugs in phase I and phase II clinical trials for systemic sclerosis
Melody P. Chung, Lorinda S Chung · 2020 · Expert Opinion on Investigational Drugs
Idiopathic Pulmonary Fibrosis: From Common Microscopy to Single-Cell Biology and Precision Medicine
Moisés Selman, Annie Pardo · 2024 · American Journal of Respiratory and Critical Care Medicine
Inhibition of 11β-hydroxysteroid dehydrogenase 1 alleviates pulmonary fibrosis through inhibition of endothelial-to-mesenchymal transition and M2 macrophage polarization by upregulating heme oxygenase-1
Su‐Yeon Lee, Ji-Hee Kim, Yeonhwa Song, Sanghwa Kim, Hyo Jin Kang, Jason Kim, Yoon‐Jin Lee, Haengran Seo · 2025 · Cell Death and Disease
Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh
Mohammed Ayaz Khan, Nahed Sherbini, Sami Alyami, Abdullah Al-Harbi, Majed Abdulrahman Alghamdi, Suliman Alrajhi, Rajkumar Rajendram, Hamdan H. Al-Jahdali · 2023 · Annals of Thoracic Medicine
The Role of Sphingolipids in Regulating Vascular Permeability in Idiopathic Pulmonary Fibrosis
Girish Jayant, Stephen J. Kuperberg, Kaumudi Somnay, Raj Wadgaonkar · 2023 · Biomedicines
Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies
Robert J. Kaner, Ednan K. Bajwa, Moustapha El-Amine, Eduard Gorina, Renu Gupta, Howard M. Lazarus, Tracy Luckhardt, Majd Mouded, Kaity Posada, Luca Richeldi et al. · 2019 · American Journal of Respiratory and Critical Care Medicine
Pterostilbene alleviates pulmonary fibrosis by regulating ASIC2
Yanfang Peng, Yingwen Zhang, Yabing Zhang, Xiuping Wang, Yukun Xia, Taisheng Ye, Zhaoyan Wu, Haoliang Ke · 2021 · Chinese Medicine
Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration
Ikeda, Satoshi, Sekine, Akimasa, Baba, Tomohisa, Kato, Terufumi, Katano, Takuma, Tabata, Erina, Shintani, Ryota, Yamakawa, Hideaki, Oda, Tsuneyuki, Okuda, Ryo et al. · 2022 · Medicine
13-Methylpalmatine alleviates bleomycin-induced pulmonary fibrosis by suppressing the ITGA5/TGF-β/Smad signaling pathway
Qin Mao, Jiajing Liu, Yu Yan, Gang Wang, Miao Zhang, Zhuo Wang, Xiaowei Wen, Zefeng Jiang, Haijing Li, Jing Li et al. · 2025 · Phytomedicine
Impact of reduction in antifibrotic treatment on mortality in idiopathic pulmonary fibrosis
Simon Porse, Nils Hoyer, Saher Burhan Shaker · 2022 · Respiratory Medicine
Fibrotic Pulmonary Sarcoidosis—From Pathogenesis to Management
Ewa Łyżwa, Jacek Wakuliński, Monika Szturmowicz, Witold Zbyszek Tomkowski, Małgorzata Sobiecka · 2025 · Journal of Clinical Medicine
Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?
Conal Hayton, Nazia Chaudhuri · 2017 · Drugs & Aging
Is chronic exposure to air pollutants a risk factor for the development of idiopathic pulmonary fibrosis?
Valérie Siroux, Bruno Crestani · 2018 · European Respiratory Journal
[Human umbilical cord mesenchymal stem cell-derived exosomes alleviate pulmonary fibrosis in mice by inhibiting epithelial-mesenchymal transition].
Jing Yang, Huazhong Hu, Shuqin Zhang, Linrui Jiang, Yuanxiong Cheng, Haojun Xie, Xiaoyan Wang, Jiaohua Jiang, Hong Wang, Qun Zhang · 2020 · PubMed Central
Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
Bryan T. Kelly, Viengneesee Thao, Timothy M. Dempsey, Lindsey R. Sangaralingham, Stephanie R. Payne, Taylor Teague, Teng Moua, Nilay D. Shah, ANDREW HAR LIMPER · 2021 · BMC Pulmonary Medicine
Tetraethylthiuram disulphide alleviates pulmonary fibrosis through modulating transforming growth factor-β signalling
Hongchao Jiang, Yaxue Zhao, Huirong Tang, Shixin Duan, Mengkai Li, Xinyi Yang, Jingting Liu, Xinyi Lou, Yuanyuan Cai, Wenjuan Zhao et al. · 2021 · Pharmacological Research
Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on real-world clinical data
Jiwon Kim, Chiwook Chung, Hyo Sin Cho, Ho Cheol Kim · 2023 · PLoS ONE
The Lung Transplant Candidate, Indications, Timing, and Selection Criteria
Hannah C. Mannem, Meghan M. Aversa, Thomas Keller, Siddhartha G. Kapnadak · 2023 · Clinics in Chest Medicine
Combined therapy with pirfenidone and nintedanib counteracts fibrotic silicosis in mice
Lu Bai, Jiaxin Wang, Xue Wang, Jixin Wang, Wei Zeng, Junling Pang, Tiantian Zhang, Shengxi Li, Meiyue Song, Yiwei Shi et al. · 2024 · British Journal of Pharmacology
Advancements in nanotechnology for targeted drug delivery in idiopathic pulmonary fibrosis: a focus on solid lipid nanoparticles and nanostructured lipid carriers
Suriya Prakaash KK, Damodharan Narayanasamy · 2025 · Drug Development and Industrial Pharmacy
Survival and lung function decline in patients with definite, probable and possible idiopathic pulmonary fibrosis treated with pirfenidone
Ondřej Májek, Jakub Gregor, Nesrin Moğulkoç, Katarzyna B. Lewandowska, Martina Šterclová, Veronika Müller, Marta Hájková, Mordechai Reuven Kramer, Jasna Tekavec-Trkanjec, Dragana M. Jovanović et al. · 2022 · PLoS ONE
Prognostic impact of an early marginal decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone
Masato Kono, Yutaro Nakamura, Noriyuki Enomoto, Go Saito, Yu Koyanagi, Koichi Miyashita, Akari Tsutsumi, Takeshi Kobayashi, Hideki Yasui, Hironao Hozumi et al. · 2019 · Respiratory Investigation
Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study
Franck Rahaghi, Zeenat Safdar, Anne Whitney Brown, João A. de Andrade, Kevin R. Flaherty, Robert J. Kaner, Christopher S. King, María L. Padilla, Imre Noth, Mary Beth Scholand et al. · 2020 · BMC Pulmonary Medicine
Effect of a Patient Support Program for Idiopathic Pulmonary Fibrosis Patients on Medication Persistence: A Retrospective Database Analysis
Aimee M. Near, Chakkarin Burudpakdee, Shilpa Viswanathan, Shuchita Kaila · 2021 · Advances in Therapy
Pirfenidone mitigates TGF-β1-mediated fibrosis in an idiopathic inflammatory myositis-associated interstitial lung disease model
Habib Layoun, Joelle Hajal, Youakim Saliba, Viviane Smayra, Bassem Habr, Nassim Farès · 2022 · Cytokine
Idiopathic pulmonary fibrosis: What primary care physicians need to know
Leslie B. Tolle, Brian D. Southern, Daniel A. Culver, Jeffrey Craig Horowitz · 2018 · Cleveland Clinic Journal of Medicine
Diagnostic and Therapeutic Applications of Extracellular Vesicles in Interstitial Lung Diseases
Abdulrahman Ibrahim, Ahmed Ibrahim, Tanyalak Parimon · 2021 · Diagnostics
Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases
Jia Liu, Faping Wang, Yiwen Hong, Fengming Luo · 2024 · Heliyon
Effect of Antifibrotic Use on Mortality in Patients with Idiopathic Pulmonary Fibrosis
Huiping Xu, Siu Lui Hui, Joyce Sujin Lee, Zuoyi Zhang, R. Boente · 2024 · Annals of the American Thoracic Society
Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use
Katherine Ann Lyseng-Williamson · 2017 · Drugs & Therapy Perspectives
Clinical Trials in IPF: What Are the Best Endpoints?
Paolo Spagnolo, Elisabetta Cocconcelli, Vincent Cottin · 2018 · Respiratory medicine
The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis
Vincent Cottin, Isabella Annesi‐Maesano, Andreas Günther, Liam Galvin, Michael Kreuter, Pippa Powell, Antje Prasse, George Reynolds, Luca Richeldi, Paolo Spagnolo et al. · 2019 · European Respiratory Journal
Current Treatments in the Management of Idiopathic Pulmonary Fibrosis: Pirfenidone and Nintedanib
Conal Hayton, Nazia Chaudhuri · 2017 · Clinical Medicine Insights Therapeutics
Eligibility for anti‐fibrotic treatment in idiopathic pulmonary fibrosis depends on the predictive equation used for pulmonary function testing
Andrew Burgess, Ken Goon, John Daniel Brannan, John Attia, Kerrin L. Palazzi, Christopher J. Oldmeadow, Tamera J. Corte, Ian Glaspole, Nicole S L Goh, Gregory J. Keir et al. · 2019 · Respirology
Improving Survival in Idiopathic Pulmonary Fibrosis
Harold R. Collard · 2017 · CHEST Journal
The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis
Stefano Kette, Nicolò Reccardini, Francesco Salton, Paola Confalonieri, Alessia Giovanna Andrisano, Maria I. Chianese, Anna De Nes, Marta Maggisano, Alessandra Galantino, Salvatore Nicolosi et al. · 2025 · Pharmaceuticals